Study to Assess in Home Use of Evolocumab (AMG 145) Administration Using Either an Automated Mini-doser or a Prefilled Autoinjector/Pen

PHASE3CompletedINTERVENTIONAL
Enrollment

164

Participants

Timeline

Start Date

July 11, 2013

Primary Completion Date

November 15, 2013

Conditions
Primary HypercholesterolemiaMixed Dyslipidemia
Interventions
BIOLOGICAL

Evolocumab AMD

Evolocumab subcutaneous injection using a single use, disposable AMD containing 3.5 mL deliverable volume.

BIOLOGICAL

Evolocumab AI/pen

Evolocumab subcutaneous injection using a handheld mechanical (spring-based) prefilled AI/Pen, each containing 1.0 mL deliverable volume.

Trial Locations (27)

13104

Research Site, Manlius

16635

Research Site, Duncansville

19446

Research Site, Lansdale

30328

Research Site, Atlanta

30342

Research Site, Atlanta

30501

Research Site, Gainesville

32086

Research Site, Saint Augustine

33952

Research Site, Port Charlotte

37203

Research Site, Nashville

38305

Research Site, Jackson

40504

Research Site, Lexington

43302

Research Site, Marion

43907

Research Site, Cadiz

75231

Research Site, Dallas

78731

Research Site, Austin

85020

Research Site, Phoenix

91360

Research Site, Thousand Oaks

91436

Research Site, Encino

92780

Research Site, Tustin

93003

Research Site, Ventura

04240

Research Site, Lewiston

01432

Research Site, Ayer

V5G 1T4

Research Site, Burnaby

N5W 6A2

Research Site, London

N7T 4X3

Research Site, Sarnia

M9V 4B4

Research Site, Toronto

H9R 3J1

Research Site, Pointe-Claire

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Amgen

INDUSTRY

NCT01879319 - Study to Assess in Home Use of Evolocumab (AMG 145) Administration Using Either an Automated Mini-doser or a Prefilled Autoinjector/Pen | Biotech Hunter | Biotech Hunter